AtaCor Medical has closed $28 million Series C financing round led by Arboretum Ventures, with participation from existing investors Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners, to support the FDA submission of its extravascular (EV) temporary pacing lead system and the completion of a pilot study for its third generation EV-ICD (Implantable Cardioverter Defibrillator, ICD) lead system.

AtaCor’s proprietary EV pacing and defibrillation lead systems are designed to deliver critical CRM therapy without placing any hardware inside the patient’s heart, leaving the heart intact and protected for future care.

AtaCor’s technology has the potential to significantly improve the lives of millions of people who rely on pacemakers and ICDs for life-sustaining rhythm management,” said Jan Garfinkle, Founder and Managing Partner of Arboretum Ventures. We welcome the Arboretum team to AtaCor and this investment supports our efforts to bring AtaCor’s novel products to patients,” said Rick Sanghera, CEO of California-based AtaCor Medical, which is dedicated to advancing the standard of care in rhythm management.

en_GBEnglish (UK)